

BC Cancer ST Program Updates for May 2026

AFFECTED APPLICATION(S)	PowerChart
AFFECTED AREA(S)	BC Cancer Sites / VCH Oncology Sites
NET NEW, OR UPDATE TO EXISTING BUILD	Update to Existing Build


What has Changed?

Any changes released that affect Oncology Regimens and PowerPlans/Cycles for the **BC Cancer Systemic Therapy (ST) Program** will be communicated monthly via Special Bulletin.

These notification changes are important for Nursing staff, Pharmacy, and Providers to be aware of for their patient’s care.

For Providers:

- For PowerPlans that are versioned: If your patient has already started on a Regimen, when you order the next cycle PowerPlan, a pop-up window will appear to indicate a new version is required.
 - Click Yes to accept the new version.
 - **Do not** use the Copy Forward functionality to ensure that the updates apply.



- **IMPORTANT:** Any change from the standard treatment regimen (dose modification, addition of premed, etc.) in the previous cycle will need to be manually added to the cycle that is being ordered with the new version (see additional documentation regarding versioning).

Please see this month's changes below.

Protocols: BRAVCMPO

Cycles/PowerPlans: Associated Regimen and Pretreatment Plan

Changes:

- Created new Pretreatment Plan for BRAVCMPO protocol

ONCP BR BRAVCMPO Pretreatment Plan, Baseline Labs (Day 1) (Future Pending) *Est. 16-Apr-2026 08

			Component			Day 1	
						Future Pending	
						*Est. 16-Apr-2026 08:...	
						Actions	
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>		CBC and Differential Blood, once, Order for future visit			Planned	
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>		Creatinine and Estimated GFR Blood, once, Order for future visit			Planned	
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>		Bilirubin Total Blood, once, Order for future visit			Planned	
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>		Alanine Aminotransferase Blood, once, Order for future visit			Planned	
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>		Alkaline Phosphatase Blood, once, Order for future visit			Planned	

- Added new plan to Regimen

ONC BR BRAVCMPO (Pending)

▶ Show additional details

+ Add Document Response View Responses

▶	ONCP BR BRAVCMPO Pretreatment Plan	*Est. Start Date: 02-May-2026
<input type="button" value="Start"/>		<input type="button" value="Skip"/>
<input checked="" type="checkbox"/>	ONCP BR BRAVCMPO - Cycle 1	*Est. Start Date: 02-May-2026
<input checked="" type="checkbox"/>	ONCP BR BRAVCMPO - Cycle 2	*Est. Start Date: 30-May-2026

Versioning: No

Jira: CST-363373

Protocols: CNELTZRT, CNAJZRT and CNAJ12TZRT

Cycles/PowerPlans: ONCP CN CNELTZRT Concurrent, ONCP CN CNAJ12TZRT Concurrent, ONCP CN CNAJZRT Concurrent

Changes:

In the Prescriptions Phase:

- Updated the special instructions for temozolomide to say

“Take once daily 1 hour (30 minutes to 2 hours is acceptable) prior to RT especially in the first week of treatment, and in AM on days without RT until completion of three week RT course”

ONCP CN CNELTZRT Concurrent (PO) - Cycle 1, Prescriptions (Future Pending)

Link to Protocol: Treatment of Elderly Newly Diagnosed Glioma Patie

Revised: 1 May 2026

DUAL MODALITY

Pre-Chemo Metrics

Details for **temozolomide (temozolomide - oncology)**

Details | Order Comments | Offset Details

*Dose	*Route of Admini...	*Frequency	Duration	*Dis
75 mg/m2	PO	qdaily		3 w

PRN: [dropdown]

Special Instructions: Take once daily 1 hour (30 minutes to 2 hours is acceptable) prior to RT especially in the first week of treatment, and in AM on days without RT until completion of three week RT course

Drug Form:

Start Date/Time: [dropdown] PDT

Versioning: Yes

Jira: CST-362691

Protocols: LYDARCBDF, UMYTEC, MYBSD

Cycles/PowerPlans: All associated PowerPlans

Changes:

ONCP LYDARCBDF Cycle 1, Cycle 2, Cycles 3 to 6, Cycles 7+ and Pretreatment:

- Pretreatment Plan: changed urea to unselected
- Next Cycle Labs:
 - Changed urea to unselected
 - Removed all random glucose and b2- macroglobulin tests

ONCP UMYTEC (Inpatient) Cycle 1 PP:

- Outpatient Next Cycle Labs:
 - Changed urea, sodium and potassium to unselected
 - Removed random glucose tests

ONCP UMYTEC (Outpatient) Cycle 1 PP:

- Next Cycle Labs:
 - **Changed** urea, sodium+potassium to unselected for Day 12 ONLY
 - **Removed** random glucose tests
- Chemotherapy phase: - **added** yellow note to say “Ensure antiviral VZV prophylaxis in in place”; position immediately below yellow note starting with “Per physician’s clinical judgement...” under Treatment Regimen.

ONCP UMYTEC Cycles 2+:

- Next Cycle Labs:
 - **Changed** urea, sodium+potassium to unselected
 - **Removed** random glucose and beta2 microglobulin tests
- Chemotherapy phase: - **added** yellow note to say “Ensure antiviral VZV prophylaxis in in place”; position immediately below Treatment Regimen note.

ONCP MYBSD Cycle 1 and Cycles 2+:

- Next Cycle Labs:
 - **Changed** urea to unselected (put below magnesium level)
 - **Removed** beta 2 microglobulin test
- Chemotherapy phase: **Replaced** entire yellow note starting with “Per physician’s clinical judgement...valacyclovir daily” to say “Ensure antiviral VZV prophylaxis in in place”

ONCP MY MYBSD Cycle 1 - Cycle 1, Chemotherapy (Day 1, 8, 15) (Future)	
Component	
Link to Protocol: Treatment of Multiple Myeloma using Bortezomib, Selinexor, and Dexamethasone With or Without Cyclophosphamide	
Revised: 2 Dec 2024	
Pre-Chemo Metrics	
May proceed with treatment on Day 1 if:	
Neutrophils Greater Than or Equal to $0.5 \times 10^9/L$ within 96 hours	
Platelet Count Greater Than or Equal to $50 \times 10^9/L$ within 96 hours	
Bilirubin Less Than or Equal to $1.5 \times ULN$ within 96 hours	
Creatinine Clearance per protocol within 96 hours	
Treatment Regimen	
Ensure antiviral VZV prophylaxis is in place	

ONCP MY UMYTEC teclistamab Cycles 2+ - Cycle 2, Labs (Day 8, 15, 22, 29) (Future Pending) *Est. 21-Apr-2026 08:00 PDT - 28 Days				
Component	Day 8	Day 15	Day 22	Day 29
	Future Pending	Future Pending	Future Pending	Future Pending
	*Est. 21-Apr-2026 08:00...	*Est. 28-Apr-2026 08:00...	*Est. 05-May-2026 08:00...	*Est. 12-May-2026 08:00...
	Actions	Actions	Actions	Actions
<input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Immunoglobulin Light Chains Free Panel (Serum K/L Fr... Blood, once, Order for future visit				Planned
<input checked="" type="checkbox"/> If clinically indicated:				
<input type="checkbox"/> <input checked="" type="checkbox"/> CBC and Differential Blood, once, Order for future visit				
<input type="checkbox"/> <input checked="" type="checkbox"/> Sodium and Potassium Panel (Electrolytes Panel Outpat... Blood, once, Order for future visit				
<input type="checkbox"/> <input checked="" type="checkbox"/> Urea Level Blood, once, Order for future visit				
<input type="checkbox"/> <input checked="" type="checkbox"/> Calcium Level				

Versioning: Yes

Jira: CST-362513

Protocols: MYBLDF, MYBLDPRE, MYBORMTN, MYBORPRE, MYBORREL, MYMPBOR, MYCARDEX, MYCARLD, UMYISACARD, UMYISAPOMD, LYDARCBDF, MYDARDBD, MYDARCBDF, MYDARLDF, MYDARLD, UMYLDF, MYLDREL, MYLENMTN, MYMP, UMYPOMDEX

Cycles/PowerPlans: All associated PowerPlans

Changes:

For Baseline Labs Phase:

- Changed urea, sodium, and potassium to unselected

For Labs Phase:

- Changed urea, sodium, and potassium to unselected
- Delete ALL random glucose and beta 2-microglobulin orders

ADD TO FAVORITE CHECK ALERTS COMMENTS

ONCP MY MYDARBD Cycle 2 - Cycle 2, Labs (Day 8, 15, 22, 29) (Future Pending) *Est. 21-Apr-2026 08:00 PDT - 28 Days				
Component	Day 8	Day 15	Day 22	Day 29
	Future Pending	Future Pending	Future Pending	Future Pending
	*Est. 21-Apr-2026 08:00...	*Est. 28-Apr-2026 08:00...	*Est. 05-May-2026 08:00...	*Est. 12-May-2026 08:00...
	Actions	Actions	Actions	Actions
<input checked="" type="checkbox"/> If clinically indicated:				
<input type="checkbox"/> <input checked="" type="checkbox"/> CBC and Differential Blood, once, Order for future visit				
<input type="checkbox"/> <input checked="" type="checkbox"/> Creatinine and Estimated GFR Blood, once, Order for future visit				
<input type="checkbox"/> <input checked="" type="checkbox"/> Sodium and Potassium Panel (Electrolytes Panel Outpat... Blood, once, Order for future visit				
<input type="checkbox"/> <input checked="" type="checkbox"/> Urea Level Blood, once, Order for future visit				
<input type="checkbox"/> <input checked="" type="checkbox"/> Bilirubin Total Blood, once, Order for future visit				
<input type="checkbox"/> <input checked="" type="checkbox"/> Alanine Aminotransferase				

For all VZV prophylaxis notes:

- Replaced yellow note starting with "Per physician's clinical judgementvalacyclovir daily" with "Ensure antiviral VZV prophylaxis is in place"

ONCP MY MYDARBD Cycle 2 - Cycle 2, Chemotherapy (Day 1, 8, 15, 22) (Futu	
Component	
<input checked="" type="checkbox"/>	salbutamol 5 mg, nebulized, q20min, PRN shortness of breath or wheezi...
	Treatment Regimen
	Ensure antiviral VZV prophylaxis is in place
<input checked="" type="checkbox"/>	Zero Time

For PowerPlans Cycle 2 and onwards with Daratumumab orders:

- Under the *Patient to take own supply* note, added yellow note "If no reaction after 4 consecutive doses of daratumumab, may discontinue acetaminophen, loratadine/diphenhydramine, and montelukast"

ONCP MY MYDARBD Cycle 2 - Cycle 2, Chemotherapy (Day 1, 8, 15, 22) (Fu	
Component	
	Bilirubin Less Than or Equal to 1.5 x ULN within 96 hours
	eGFR or creatinine clearance per protocol within 96 hours
	Pre-Medications
	Ensure patient has taken steroids with all other pre-medications prior to daratumumab
	Refer to Prescriptions phase for dexamethasone or predniSONE orders
	Patient to take own supply of pre-medications. RN/Pharmacist to confirm
	If no reaction after 4 consecutive doses of daratumumab, may discontinue acetaminophen, loratadine/diphenhydramine, and montelukast

For First Dose Subcutaneous Cycle 1 PowerPlans and all LYDARCBDF cycles:

- Removed yellow note "As needed during infusion" and associated two meds - acetaminophen and diphenhydramine q4h PRN

Versioning: Yes

Jira: CST-362241

Protocols: LYPOLABR

Cycles/PowerPlans: ONCP LY LYPOLABR Cycle 1 and ONCP LY LYPOLABR Cycles 2 to 6

Changes:

ONCP LY LYPOLABR Cycle 1 riTUXimab phase:

- Added a yellow CDS note above rituximab order: Initial Infusion: riTUXimab naïve or as clinically indicated due to prior intolerance
- Added a yellow CDS note under rituximab order: Subsequent Infusion: Patient did not tolerate a full dose of IV riTUXimab (experienced severe reactions requiring early termination) in the previous treatment
- Added an unselected riTUXimab - oncology order: 375 mg/m², IV, once oncology, drug form: bag. Comments: Subsequent Infusion: Infuse 50 mL (of 250 mL bag) or 100 mL (of 500 mL bag) of the dose over 30 minutes, then infuse the remainder of the bag over 1 hour. Refer to Protocol/PDTM for monitoring requirements. If flushing, dyspnea, rigors, rash, pruritus, vomiting, chest pain, any other new acute discomfort or exacerbation of any existing symptoms occur, stop infusion and page physician
- Added a yellow CDS note: Subcutaneous Injection: Patient tolerated a full dose of IV riTUXimab (no severe reactions requiring early termination)
- Added an unselected riTUXimab subcut - oncology: 1,400 mg, subcutaneous, once oncology, administer over: 5 minute, drug form: syringe-inj. Comments: Subcutaneous Injection: Inject into abdomen. Observe for 15 minutes after administration
- Added a turquoise CDS note: During treatment with subcutaneous riTUXimab, administer other subcutaneous drugs at alternative injection sites whenever possible

ONCP LY LYPOLABR Cycle 1 - Cycle 1, riTUXimab (Day 1) Future Pending) *Est. 09-Apr-2026 08:00 PDT - 21 Days			Day 1
		Component	Future Pending
			*Est. 09-Apr-2026 08:...
			Actions
		For SPH and VGH refer to PDTM for riTUXimab monitoring requirements	
		Initial Infusion: riTUXimab naïve or as clinically indicated due to prior intolerance	
<input checked="" type="checkbox"/>		riTUXimab (riTUXimab - oncology) 375 mg/m ² , IV, once oncology, drug form: bag Initial Infusion: Start infusion at 50 mg/hour, after 1 hour, increase by 50 mg/hour every 30 minutes to maximum 400 mg/hour unless toxicity occurs. R...	0 min Planned
		Subsequent Infusion: Patient did not tolerate a full dose of IV riTUXimab (experienced severe reactions requiring early termination) in the previous treatment	
<input type="checkbox"/>		riTUXimab (riTUXimab - oncology) 375 mg/m ² , IV, once oncology, drug form: bag Subsequent Infusion: Infuse 50 mL (of 250 mL bag) or 100 mL (of 500 mL bag) of the dose over 30 minutes, then infuse the remainder of the bag over 1 ...	0 min
		Subcutaneous Injection: Patient tolerated a full dose of IV riTUXimab (no severe reactions requiring early termination)	
<input type="checkbox"/>		riTUXimab (riTUXimab subcut - oncology) 1,400 mg, subcutaneous, once oncology, administer over: 5 minute, drug form: syringe-inj Subcutaneous Injection: Inject into abdomen. Observe for 15 minutes after administration	0 min
		During treatment with subcutaneous riTUXimab, administer other subcutaneous drugs at alternative injection sites whenever possible	

ONCP LY LYPOLABR Cycles 2 to 6 riTUXimab phase:

- Revised yellow CDS note due to spelling error: Initial Infusion: riTUXimab naïve or as clinically indicated due to prior intolerance

ONCP LY LYPOLABR Cycles 2 to 6 - Cycle 2, riTUXimab (Treatment 2) (Future Pending) *Est. 10-Apr-2026 08:00 PDT - 21 Days

Component
<input checked="" type="checkbox"/> salbutamol 5 mg, nebulized, q20min, PRN shortness of breath or wheezing, order duration: 3 doses or times, drug form: neb Treatment Regimen
<input checked="" type="checkbox"/> Zero Time
<input checked="" type="checkbox"/> For SPIH and VGH refer to PDTM for riTUXimab monitoring requirements <input checked="" type="checkbox"/> Initial Infusion: riTUXimab naive or as clinically indicated due to prior intolerance
<input type="checkbox"/> riTUXimab (riTUXimab - oncology)

Versioning: Yes

Jira: CST-362711

Protocols: LYGEMOXPEG

Cycles/PowerPlans: ONCP LY LYGEMOXPEG

Changes:

Chemotherapy Phase:

- Added yellow CDS note "If dexamethasone IV is being given for prior oxaliplatin hypersensitivity, deselect dexamethasone PO"
- Linked dexamethasone PO dose with dexamethasone IV dose

ONCP LY LYGEMOXPEG - Cycle 1, Chemotherapy (Day 1, 8) (Future Pending) *Est. 16-Apr-2026 08:00 PDT - 21 Days

Component	Day 1	Day 8
Pre-Medications	Future Pending *Est. 16-Apr-2026 08:00 PDT	Future Pending *Est. 23-Apr-2026 08:00 PDT
<input checked="" type="checkbox"/> ondansetron 8 mg, PO, once oncology, drug form: tab, Use Patient Supply Between 30 and 60 minutes prior to treatment. Day 1	-30 min Planned	
<input checked="" type="checkbox"/> If dexamethasone IV is being given for prior oxaliplatin hypersensitivity, deselect dexamethasone PO		
<input checked="" type="checkbox"/> dexamethasone 8 mg, PO, once oncology, drug form: tab, Use Patient Supply Between 30 and 60 minutes prior to treatment. Day 1	-30 min Planned	

- Added yellow CDS note 'For prior oxaliplatin hypersensitivity reactions (Grade 1 or 2):'
- Added dexamethasone, diphenhydramine and famotidine premeditations

ONCP LY LYGEMOXPEG - Cycle 1, Chemotherapy (Day 1, 8) (Future Pending) *Est. 16-Apr-2026 08:00 PDT - 21 Days		
Component	Day 1	Day 8
	Future Pending *Est. 16-Apr-2026 08:...	Future Pending *Est. 23-Apr-2026 08:...
	Actions ▾	Actions ▾
For prior oxaliplatin hypersensitivity reactions (Grade 1 or 2):		
<input type="checkbox"/> dexamethasone 20 mg, IV, once oncology, administer over: 15 minute, drug form: inj 45 minutes prior to oxaliplatin. Day 1	-15 min	
<input type="checkbox"/> diphenhydrAMINE 50 mg, IV, once oncology, administer over: 15 minute, drug form: inj Y-site compatible with famotidine. 30 minutes prior to oxaliplatin. Day 1	0 min	
<input type="checkbox"/> famotidine 20 mg, IV, once oncology, administer over: 15 minute, drug form: inj Y-site compatible with diphenhydrAMINE. 30 minutes prior to oxaliplatin. Day 1	0 min	

Versioning: Yes

Jira: CST-362960

Protocols: GOCXPEMCR

Cycles/PowerPlans: ONCP GO GOCXPEMCR Cycle 1 and ONCP GO GOCXPEMCR Cycle 2

Changes:

ONCP GO GOCXPEMCR Cycle 1

- Update Follow Up - Clinic - Oncology On Treatment order sentence to 'Follow Up: As per Special Instructions, Prior to Day 1 treatment, Physician Specialty: Medical Oncology, Tumor Group: Gynecology'
- Add prechecked Follow Up - Clinic - Oncology On Treatment order with order sentence 'Follow Up: As per Special Instructions, Prior to Day 8 treatment, Physician Specialty: Medical Oncology, Tumor Group: Gynecology'
- Add prechecked Follow Up - Clinic - Oncology On Treatment order with order sentence 'Follow Up: As per Special Instructions, Prior to Day 15 treatment, Physician Specialty: Medical Oncology, Tumor Group: Gynecology'

ONCP GO GOCXPEMCR Cycle 1 Cycle 1, Scheduling (Initiated Pending)		
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Infusion Chemotherapy Visit	Within 2 Weeks, DUAL MODALITY, Chair Time: 300 minutes, Nurse Time: 60 minutes, ONCP GO GOCXPEMCR Cycle 1 Day 1
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Infusion Chemotherapy Visit	Within 2 Weeks, DUAL MODALITY, Chair Time: 240 minutes, Nurse Time: 45 minutes, ONCP GO GOCXPEMCR Cycle 1 Day 8
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Infusion Chemotherapy Visit	Within 2 Weeks, DUAL MODALITY, Chair Time: 240 minutes, Nurse Time: 45 minutes, ONCP GO GOCXPEMCR Cycle 1 Day 15
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Follow Up - Clinic - Oncology On Treatment	Follow Up: As per Special Instructions, Prior to Day 1 treatment, Physician Specialty: Medical Oncology, Tumor Group: Gynecology
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> +7 day Follow Up - Clinic - Oncology On Treatment	Follow Up: As per Special Instructions, Prior to Day 8 treatment, Physician Specialty: Medical Oncology, Tumor Group: Gynecology
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> +14 day Follow Up - Clinic - Oncology On Treatment	Follow Up: As per Special Instructions, Prior to Day 15 treatment, Physician Specialty: Medical Oncology, Tumor Group: Gynecology

ONCP GO GOCXPEMCR Cycle 2

- Update Follow Up - Clinic - Oncology On Treatment order sentence to 'Follow Up: As per Special Instructions, Prior to Day 1 treatment, Physician Specialty: Medical Oncology, Tumor Group: Gynecology'
- Add prechecked Follow Up - Clinic - Oncology On Treatment order with order sentence 'Follow Up: As per Special Instructions, Prior to Day 8 treatment, Physician Specialty: Medical Oncology, Tumor Group: Gynecology'
- Add CDS Note: 'If ordering Cisplatin on Cycle 2 Day 15'
- Add unchecked Follow Up - Clinic - Oncology On Treatment order with order sentence 'Follow Up: As per Special Instructions, Prior to Day 15 treatment, Physician Specialty: Medical Oncology, Tumor Group: Gynecology'

ONCP GO GOCPMCR Cycle 2 - Cycle 2, Scheduling (Initiated Pending)		
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Infusion Chemotherapy Visit	Within 2 Weeks, DUAL MODALITY, Chair Time: 285 minutes, Nurse Time: 45 minutes, ONCP GO GOCPMCR Cycle 2 Day 1
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Infusion Chemotherapy Visit	Within 2 Weeks, DUAL MODALITY, Chair Time: 240 minutes, Nurse Time: 45 minutes, ONCP GO GOCPMCR Cycle 2 Day 8
	<input checked="" type="checkbox"/> Select if ordering optional additional Cisplatin Day 15 dose	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Infusion Chemotherapy Visit	Within 2 Weeks, DUAL MODALITY, Chair Time: 240 minutes, Nurse Time: 45 minutes, ONCP GO GOCPMCR Cycle 2 Day 15
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Follow Up - Clinic - Oncology On Treatment	Follow Up: As per Special Instructions, Prior to Day 1 treatment, Physician Specialty: Medical Oncology, Tumor Group: Gynecology
<input checked="" type="checkbox"/> +7 day	<input checked="" type="checkbox"/> Follow Up - Clinic - Oncology On Treatment	Follow Up: As per Special Instructions, Prior to Day 8 treatment, Physician Specialty: Medical Oncology, Tumor Group: Gynecology
	<input checked="" type="checkbox"/> If ordering Cisplatin on Cycle 2 Day 15	
<input type="checkbox"/> +14 day	<input checked="" type="checkbox"/> Follow Up - Clinic - Oncology On Treatment	Follow Up: As per Special Instructions, Prior to Day 15 treatment, Physician Specialty: Medical Oncology, Tumor Group: Gynecology

Versioning: Yes

Jira: CST-363859

Protocols: GOOVYCPO

Cycles/PowerPlans: ONCP GO GOOVYCPO (PO) - Cycle 1

Changes:

Prescriptions Phase:

- **Updated** Revised date to "1 May 2026"
- **Removed** cyclophosphamide 25 mg PO option (only 50 mg option remains)

Order	Prescription	Status	Dose ...	Details
ONCP GO GOOVYCPO (PO) - Cycle 1, Prescriptions (Future Pending)				
	<input checked="" type="checkbox"/> Link to Protocol: Palliative Therapy for Relapsed/Progressing Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma Using Metronomic Low-Dose Oral Cyclophosphamide			
	<input checked="" type="checkbox"/> Revised: 1 May 2026			
	<input checked="" type="checkbox"/> Pre-Chemo Metrics			
	<input checked="" type="checkbox"/> Neutrophils Greater Than $1.0 \times 10^9/L$ within 96 hours			
	<input checked="" type="checkbox"/> Platelet Count Greater Than or Equal to $100 \times 10^9/L$ within 96 hours			
	<input checked="" type="checkbox"/> Treatment Regimen			
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> cyclophosphamide		50 mg, PO, qdaily, drug form: tab, dispense qty: 28 day	

Versioning: Y

Jira: CST-363124

Protocols: UGUNMPDAR

Cycles/PowerPlans: ONCP GU UGUNMPDAR (PO) – Cycle 1

Changes:

Next Cycle Labs Phase:

- Remove optional Hba1c, calcium and glucose

ONCP GU UGUNMPDAR (PO) - Cycle 1, Next Cycle Labs (Day 1) (Future Pending) *Est. 17-Jul-2026 12:19 PDT - 1 Days		
Component		Day 1
		Future Pending
		*Est. 17-Jul-2026 12:19 PDT
		Actions
<input checked="" type="checkbox"/>	PSA - Known/Suspected Prostate Cancer Blood, once, Order for future visit	Planned
	If clinically indicated:	
<input type="checkbox"/>	Albumin Level Blood, once, Order for future visit	
<input type="checkbox"/>	Bilirubin Total Blood, once, Order for future visit	
<input type="checkbox"/>	INR Blood, once, Order for future visit	
<input type="checkbox"/>	Alanine Aminotransferase Blood, once, Order for future visit	
<input type="checkbox"/>	Creatinine and Estimated GFR Blood, once, Order for future visit	
<input type="checkbox"/>	Sodium and Potassium Panel (Electrolytes Panel Output... Blood, once, Order for future visit	
<input type="checkbox"/>	Thyroid Stimulating Hormone Blood, once, Order for future visit	
<input type="checkbox"/>	Testosterone Level Blood, once, Order for future visit	

Lab orders removed

Versioning: Y

Jira: CST-364870

Protocols: GUMVAC

Cycles/PowerPlans: ONCP GU GUMVAC

Changes:

Next Cycle Labs Phase:

- Added the following optional labs to Days 15 and 22:
 - CBC and Differential
 - Creatinine and Estimated GFR
 - Total bilirubin
 - Alanine Aminotransferase

Component	Day 15	Day 22	Day 29
	Future Pending *Est. 21-Apr-2026 08:00:00	Future Pending *Est. 28-Apr-2026 08:00:00	Future Pending *Est. 05-May-2026 08:00:00
<input checked="" type="checkbox"/> CBC and Differential Blood, once, Order for future visit	Actions	Actions	Planned
<input checked="" type="checkbox"/> Creatinine and Estimated GFR Blood, once, Order for future visit			Planned
<input checked="" type="checkbox"/> Alanine Aminotransferase Blood, once, Order for future visit			Planned
<input checked="" type="checkbox"/> Alkaline Phosphatase Blood, once, Order for future visit			Planned
<input checked="" type="checkbox"/> Bilirubin Total Blood, once, Order for future visit			Planned
<input checked="" type="checkbox"/> Lactate Dehydrogenase Blood, once, Order for future visit			Planned
⚡ If clinically indicated:			
<input type="checkbox"/> CBC and Differential Blood, once, Order for future visit			
<input type="checkbox"/> Creatinine and Estimated GFR Blood, once, Order for future visit			
<input type="checkbox"/> Alanine Aminotransferase Blood, once, Order for future visit			
<input type="checkbox"/> Bilirubin Total Blood, once, Order for future visit			

Versioning: Yes

Jira: CST-364966

Protocols: MY/LY Protocols

Cycles/PowerPlans: All treatment PowerPlans

Changes:

Prescriptions Phase:

- Removed "round to nearest 25 mg" from cyclophosphamide order comment

Prescriptions (Inpatient only) Phase:

- Removed "round to nearest 25 mg" from cyclophosphamide order comment

Component | Status | DOS

ONCP MY MYBSD Cycle 1 - Cycle 1, Prescriptions (Future Pending)

Provider to ensure that patient has anti-emetic premedications prior to taking
selinexor

Dose modification:
selinexor

Select one of the following. Refer to protocol for steroid dosing options:
dexamethasone

predniSONE

Optional Cyclophosphamide:
cyclophosphamide

▼ Details for **cyclophosphamide**

Details | Order Comments | Offset Details

Order comments

Prescription is part of a combined IV/PO protocol. Dispense quantity = 1 cycle

Impacted PowerPlans:

- ONCP MY MYBSD Cycle 1
- ONCP MY MYBSD Cycles 2+
- ONCP LY LYDARCBDF Cycle 1
- ONCP LY LYDARCBDF Cycle 2
- ONCP LY LYDARCBDF Cycles 3 to 6
- ONCP LY LYDARCBDF Cycles 7+
- ONCP MY MYBORPRE Twice Weekly
- ONCP MY MYBORPRE Weekly
- ONCP MY MYBORREL Twice Weekly
- ONCP MY MYBORREL Weekly
- ONCP MY MYCARDEX Cycle 1
- ONCP MY MYCARDEX Cycles 2+
- ONCP MY MYCARDEX Cyclophosphamide Option Cycle 1
- ONCP MY MYCARDEX Cyclophosphamide Option Cycles 2+
- ONCP MY MYDARBD Cycle 2
- ONCP MY MYDARBD Cycles 3 and 4
- ONCP MY MYDARBD Cycles 5 to 8
- ONCP MY MYDARBD Cycles 9+
- ONCP MY MYDARBD First Dose IV Cycle 1
- ONCP MY MYDARBD First Dose IV Split Dosing Cycle 1
- ONCP MY MYDARBD First Dose Subcutaneous Cycle 1
- ONCP MY MYDARCBDF Cycle 2
- ONCP MY MYDARCBDF Cycles 10+
- ONCP MY MYDARCBDF Cycles 3 to 6
- ONCP MY MYDARCBDF Cycles 7 to 9
- ONCP MY MYDARCBDF First Dose IV Cycle 1
- ONCP MY MYDARCBDF First Dose IV Split Dosing Cycle 1
- ONCP MY MYDARCBDF First Dose Subcutaneous Cycle 1
- ONCP MY MYDARLD Female of Childbearing Potential (FCBP) Cycle 2

ONCP MY MYDARLD Female of Childbearing Potential (FCBP) Cycles 3 to 6
 ONCP MY MYDARLD Female of Childbearing Potential (FCBP) Cycles 7+
 ONCP MY MYDARLD Female of Childbearing Potential (FCBP) First Dose IV Cycle 1
 ONCP MY MYDARLD Female of Childbearing Potential (FCBP) First Dose Subcutaneous Cycle 1
 ONCP MY MYDARLD Female of Childbearing Potential FCBP First Dose IV Split Dosing Cycle1
 ONCP MY MYDARLD Non Childbearing Potential (NCBP) Cycle 2
 ONCP MY MYDARLD Non Childbearing Potential (NCBP) Cycles 3 to 6
 ONCP MY MYDARLD Non Childbearing Potential (NCBP) Cycles 7+
 ONCP MY MYDARLD Non Childbearing Potential (NCBP) First Dose IV Cycle 1
 ONCP MY MYDARLD Non Childbearing Potential (NCBP) First Dose IV Split Dosing Cycle 1
 ONCP MY MYDARLD Non Childbearing Potential (NCBP) First Dose Subcutaneous Cycle 1
 ONCP MY MYMPBOR Cycles 1 and 2
 ONCP MY MYMPBOR Cycles 3+
 ONCP MY UMYISACARD Cycle 1
 ONCP MY UMYISACARD Cycles 2+
 ONCP MY UMYISAPOMD Female of Childbearing Potential (FCBP) Cycle 1
 ONCP MY UMYISAPOMD Female of Childbearing Potential (FCBP) Cycles 2+
 ONCP MY UMYISAPOMD Non Childbearing Potential (NCBP) Cycle 1
 ONCP MY UMYISAPOMD Non Childbearing Potential (NCBP) Cycles 2+
 ONCP BR BRAVCMPO - remove _mg order sentence. No changes to 50mg option
 ONCP LY LYCYCLO (PO)
 ONCP LY LYFCR PO Option Cycle 1
 ONCP LY LYFCR PO Option Cycles 2+

Versioning: Yes

Jira: CST-364561

Protocols: GOEAVDCAT and GOEAVDPNC

Cycles/PowerPlans: Associated Regimens and PowerPlans

Changes:

- Updated title of GOEAVDCAT protocol and Regimen Description to: Treatment of Endometrial Cancer using Dostarlimab with CARBOplatin and PACLitaxel

ONCP GO GOEAVDCAT Cycles 1 to 6 - Cycle 1, Chemotherapy (Day 1) (Future Pending) *Est. 18-Apr-2026 08:...

Component	Day 1
	Future Pending
	*Est. 18-Apr-2026 08:...
	Actions
Link to Protocol: Treatment of Endometrial Cancer using Dostarlimab with CARBOplatin and PACLitaxel	
Revised: 1 May 2026	
Pre-Chemo Metrics	

ONCP GO GOEAVDCAT Cycles 7+ - Cycle 7, Chemotherapy (Day 1) (Future Pending) *Est. 18-Apr-2026 08:00	
Component	Day 1 Future Pending *Est. 18-Apr-2026 08:00 Actions
Link to Protocol: Treatment of Endometrial Cancer using Dostarlimab with CARBOplatin and PACLitaxel Revised: 1 May 2026	

ONC GO GOEAVDCAT (Pending)

▼ Hide additional details

Regimen description: Treatment of Endometrial Cancer using Dostarlimab with CARBOplatin and PACLitaxel

+ Add Document Response View Responses

ONCP GO GOEAVDCAT Pretreatment Plan

Start

ONCP GO GOEAVDCAT Cycles 1 to 6 - Cycle 1

ONCP GO GOEAVDCAT Cycles 1 to 6 - Cycle 2

- Updated title of GOEAVDPNC protocol and Regimen Description to: Alternative Treatment of Endometrial Cancer using Dostarlimab with PACLitaxel NAB and CARBOplatin

ONCP GO GOEAVDPNC Cycles 1 to 6 - Cycle 1, Chemotherapy (Day 1) (Future Pending) *Est. 18-Apr-2026 08:00	
Component	Day 1 Future Pending *Est. 18-Apr-2026 08:00 Actions
Link to Protocol: Alternative Treatment of Endometrial Cancer using Dostarlimab with PACLitaxel NAB and CARBOplatin Revised: 1 May 2026	

ONCP GO GOEAVDPNC Cycles 7+ - Cycle 7, Chemotherapy (Day 1) (Future Pending) *Est. 18-Apr-2026 08:00	
Component	Day 1 Future Pending *Est. 18-Apr-2026 08:00 Actions
Link to Protocol: Alternative Treatment of Endometrial Cancer using Dostarlimab with PACLitaxel NAB and CARBOplatin Revised: 1 May 2026	

ONC GO GOEAVDPNC (Pending)

▼ Hide additional details

Regimen description: Alternative Treatment of Endometrial Cancer using Dostarlimab with PAclitaxel NAB and CARBOplatin

Document Response
 View Responses

▶
ONCP GO GOEAVDPNC Pretreatment Plan

Start

ONCP GO GOEAVDPNC Cycles 1 to 6 - Cycle 1

Versioning: Yes

Jira: CST-361725

Protocols: BRAJPNT

Cycles/PowerPlans: Associated Regimens and PowerPlans

Changes:

- Updated title of BRAJPNT protocol and Regimen Description to: *Alternative Neoadjuvant or Adjuvant Therapy for Breast Cancer using PAclitaxel NAB and Trastuzumab*

	ONCP BR BRAJPNT Cycle 1 - Cycle 1, Chemotherapy (Day 1) (Future Pending) *Est. 18-Apr-2026 08:00 PDT - 21	
	Component	Day 1
		Future Pending
		*Est. 18-Apr-2026 08:...
		Actions ▼
	Link to Protocol: Alternative Neoadjuvant or Adjuvant Therapy for Breast Cancer using PAclitaxel NAB and Trastuzumab	
	Revised: 1 May 2026	
	For patients who have received only ONE cycle of trastuzumab previously	
	Pre-Chemo Matrix	
	ONCP BR BRAJPNT Cycles 2+ - Cycle 2, Chemotherapy (Day 1) (Future Pending) *Est. 18-Apr-2026 08:00 PDT -	
	Component	Day 1
		Future Pending
		*Est. 18-Apr-2026 08:...
		Actions ▼
	Link to Protocol: Alternative Neoadjuvant or Adjuvant Therapy for Breast Cancer using PAclitaxel NAB and Trastuzumab	
	Revised: 1 May 2026	
	For patients who have received TWO cycles or more of trastuzumab previously	
	Pre-Chemo Matrix	

ONC BR BRAJPNT (Pending)

▼ Hide additional details

Regimen description: Alternative Neoadjuvant or Adjuvant Therapy for Breast Cancer using PAClitaxel NAB and Trastuzumab

+ Add Document Response View Responses

→ ONC BR BRAJPNT Pretreatment Plan

Start

🔍 ONC BR BRAJPNT Cycle 1 - Cycle 1

Versioning: Yes

Jira: CST-360787

Net New Protocols

- ONC SA SAAVGEM
- ONCP SA SAAVGEM Pretreatment Plan
- ONCP SA SAAVGEM

- ONC MY MYDBLDF Female of Childbearing Potential (FCBP) Induction Phase
- ONC MY MYDBLDF Female of Childbearing Potential (FCBP) Consolidation and Maintenance
- ONC MY MYDBLDF Female of Childbearing Potential (FCBP) Maintenance Daratumumab Restart
- ONC MY MYDBLDF Non Childbearing Potential (NCBP) Induction Phase
- ONC MY MYDBLDF Non Childbearing Potential (NCBP) Consolidation and Maintenance
- ONC MY MYDBLDF Non Childbearing Potential (NCBP) Maintenance Daratumumab Restart
- ONCP MY MYDBLDF Female of Childbearing Potential (FCBP) Pretreatment Plan
- ONCP MY MYDBLDF Female of Childbearing Potential (NCBP) Consolidation Pretreatment Plan
- ONCP MY MYDBLDF Female of Childbearing Potential (FCBP) Induction Cycle 1
- ONCP MY MYDBLDF Female of Childbearing Potential (FCBP) Induction Cycle 2
- ONCP MY MYDBLDF Female of Childbearing Potential (FCBP) Induction Cycles 3 and 4
- ONCP MY MYDBLDF Female of Childbearing Potential (NCBP) Consolidation Cycle 5
- ONCP MY MYDBLDF Female of Childbearing Potential (FCBP) Consolidation Cycle 6
- ONCP MY MYDBLDF Female of Childbearing Potential (FCBP) Maintenance Cycles 7+
- ONCP MY MYDBLDF Female of Childbearing Potential (FCBP) Daratumumab Restart Cycle 1
- ONCP MY MYDBLDF Female of Childbearing Potential (FCBP) Daratumumab Restart Cycle 2
- ONCP MY MYDBLDF Female of Childbearing Potential (FCBP) Daratumumab Restart Cycles 3 to 6
- ONCP MY MYDBLDF Female of Childbearing Potential (FCBP) Daratumumab Restart Cycles 7+
- ONCP MY MYDBLDF Non Childbearing Potential (NCBP) Pretreatment Plan
- ONCP MY MYDBLDF Non Childbearing Potential (NCBP) Induction Cycle 1
- ONCP MY MYDBLDF Non Childbearing Potential (NCBP) Induction Cycle 2
- ONCP MY MYDBLDF Non Childbearing Potential (NCBP) Induction Cycles 3 and 4
- ONCP MY MYDBLDF Non Childbearing Potential (NCBP) Consolidation Cycles 5 and 6
- ONCP MY MYDBLDF Non Childbearing Potential (NCBP) Maintenance Cycles 7+
- ONCP MY MYDBLDF Non Childbearing Potential (NCBP) Daratumumab Restart Cycle 1

- ONCP MY MYDBLDF Non Childbearing Potential (NCBP) Daratumumab Restart Cycle 2
- ONCP MY MYDBLDF Non Childbearing Potential (NCBP) Daratumumab Restart Cycles 3 to 6
- ONCP MY MYDBLDF Non Childbearing Potential (NCBP) Daratumumab Restart Cycles 7+

- ONC GU GUMCSPDAR (PO)
- ONCP GU GUMCSPDAR Pretreatment Plan
- ONCP GU GUMCSPDAR (PO)

CST-363480, CST-361113, CST-361723

Jira Ticket #	CST-364966, CST-364870, CST-364561, CST-363859, CST-363373, CST-363124, CST-362960, CST-362711, CST-362691, CST-362513, CST-362241, CST-361725, CST-360787 CST-363480, CST-361113, CST-361723
How-to questions?	http://cstcernerhelp.healthcarebc.ca
Need further support?	CST Cerner Phone Support: 1-844-214-7444